Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus chemotherapy in metastatic esophageal squamous cell carcinoma
NCT03126708Phase 2Unknown
- Sponsor
- Peking University
- Start
- Apr 2017
- Primary completion
- Apr 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Status: unknown.
02
Drugs
cetuximab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03126708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126708.